We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, CRISPR Therapeutics AG (CRSP - Free Report) was down 3.9% at $49.47. The stock's change was less than the S&P 500's daily loss of 1.62%. Elsewhere, the Dow saw a downswing of 1.87%, while the tech-heavy Nasdaq depreciated by 1.98%.
The company's stock has dropped by 2.56% in the past month, falling short of the Medical sector's gain of 5.04% and the S&P 500's loss of 0.03%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.11 per share, which would represent year-over-year growth of 13.95%. At the same time, our most recent consensus estimate is projecting a revenue of $9.28 million, reflecting a 942.7% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.92 per share and revenue of $38.88 million, which would represent changes of +23.96% and +1007.58%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 3.42% rise in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest close session, CRISPR Therapeutics AG (CRSP - Free Report) was down 3.9% at $49.47. The stock's change was less than the S&P 500's daily loss of 1.62%. Elsewhere, the Dow saw a downswing of 1.87%, while the tech-heavy Nasdaq depreciated by 1.98%.
The company's stock has dropped by 2.56% in the past month, falling short of the Medical sector's gain of 5.04% and the S&P 500's loss of 0.03%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.11 per share, which would represent year-over-year growth of 13.95%. At the same time, our most recent consensus estimate is projecting a revenue of $9.28 million, reflecting a 942.7% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.92 per share and revenue of $38.88 million, which would represent changes of +23.96% and +1007.58%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 3.42% rise in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.